Twist Bioscience (TWST) Receivables - Other (2019 - 2026)

Twist Bioscience has disclosed Receivables - Other across 8 years of filings, most recently posting $8.4 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 469.08% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (up 469.08% YoY), while the FY2025 annual figure was $3.9 million, up 89.91% from the prior year.
• Receivables - Other retreated to $8.4 million in Q1 2026, from $12.3 million in the prior quarter.
• Over the last five years, Receivables - Other for TWST reached as high as $12.3 million in Q4 2025 and fell as low as $1.0 million in Q2 2025.
• The 5-year median for Receivables - Other is $3.4 million (2022), against an average of $4.2 million.
• Annual changes were most pronounced in 2022 — Receivables - Other soared 694.5% — and 2025, when it slumped 60.15%.
• A 5-year view of Receivables - Other shows it stood at $5.3 million in 2022, then plunged by 52.42% to $2.5 million in 2023, then fell by 26.52% to $1.8 million in 2024, then surged by 569.52% to $12.3 million in 2025, then sank by 31.75% to $8.4 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $8.4 million, $12.3 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.